MedTrace Logo

Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601)

NCT02842697 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2019-01-08

No results posted yet for this study

Summary

This is a prospective, multi-center trial conducted at 1 Guangzhou and 2 Beijing centers designed to determine the diagnostic performance of virtual hepatic venous pressure gradient (vHVPG) (investigational technology) by anatomic computed tomographic angiography (CTA) for non-invasive assessment of the clinically significant portal hypertension (CSPH) in patients with compensated cirrhosis. Direct hepatic venous pressure gradient (HVPG) measurement by means of catheterization of a hepatic vein with a balloon catheter is the gold-standard method to assess the presence of CSPH, which is defined as HVPG≥10 mmHg.

Conditions

  • Hypertension, Portal

Interventions

PROCEDURE

HVPG measurement

HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter

PROCEDURE

CTA

Three-dimensional hepatic vein-portal vein model constructed with CTA images

PROCEDURE

Doppler ultrasound

Portal vein velocity measured by Doppler ultrasound

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Xiaolong Qi, M.D. · Nanfang Hospital, Southern Medical University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02842697 on ClinicalTrials.gov